Neurimmune, AstraZeneca collaborate to develop monoclonal antibody targeting transthyretin

Jan. 07, 2022 3:13 AM ETAstraZeneca PLC (AZN)By: Mamta Mayani, SA News Editor

Doctor hold a vial of monoclonal antibodies , a new treatment for coronavirus Covid-19, on a white table

Cristian Storto Fotografia/iStock via Getty Images

  • Neurimmune has entered into an exclusive global collaboration and license agreement with AstraZeneca's (NASDAQ:AZN) Alexion group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin.
  • NI006 is currently in Phase

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.